Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. DiaMedica Therapeutics Inc shares valued at $2,029,252 were purchased by STAHLBERG JAN on Aug 25 ’25. At $6.00 per share, STAHLBERG JAN acquired 338,265 shares. The insider’s holdings grew to 7,654,045 shares worth approximately $41.48 million following the completion of this transaction.
Also, STAHLBERG JAN purchased 293,601 shares, netting a total of over 1,734,918 in proceeds. Following the buying of shares at $5.91 each, the insider now holds 7,058,066 shares.
Before that, STAHLBERG JAN had added 70,414 shares to its account. In a trade valued at $421,921, the 10% Owner bought DiaMedica Therapeutics Inc shares for $5.99 each. Upon closing the transaction, the insider’s holdings increased to 70,414 shares, worth approximately $38.64 million.
As published in their initiating research note from TD Cowen on October 30, 2025, DiaMedica Therapeutics Inc [DMAC] has been a Buy. Analysts at H.C. Wainwright started covering the stock with ‘”a Buy”‘ outlook in a report released in early October. Earlier on June 22, 2023, Oppenheimer upgraded its rating. Their new recommendation was “an Outperform” for DMAC stock which previously was a “a Perform”.
Analyzing DMAC Stock Performance
On last trading session, DiaMedica Therapeutics Inc [NASDAQ: DMAC] plunged -14.10% to $5.42. The stock’s lowest price that day was $5.26, but it reached a high of $6.1 in the same session. During the last five days, there has been a drop of approximately -12.86%. Over the course of the year, DiaMedica Therapeutics Inc shares have jumped approximately 28.13%. Shares of the company reached a 52-week high of $7.49 on 09/08/25 and a 52-week low of $3.19 on 04/07/25.
Support And Resistance Levels for DiaMedica Therapeutics Inc (DMAC)
According to the 24-hour chart, there is a support level at 5.09, which, if violated, would cause prices to drop to 4.75. In the upper region, resistance lies at 5.93. The next price resistance is at 6.43. RSI (Relative Strength Index) is 31.34 on the 14-day chart, showing neutral technical sentiment.
Is DiaMedica Therapeutics Inc subject to short interest?
Stocks of DiaMedica Therapeutics Inc saw a sharp steep in short interest on 2025-10-31 dropping by -0.12 million shares to 4.12 million. Data from Yahoo Finance shows that the short interest on 2025-09-30 was 4.24 million shares. A decline of -2.85% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 16.65 of the overall float, the days-to-cover ratio (short ratio) decline to 16.65.
Which companies own the most shares of DiaMedica Therapeutics Inc (DMAC)?
In terms of DiaMedica Therapeutics Inc share price expectations, FactSet research, analysts set an average price target of 8 in the next 12 months, up nearly 26.78% from the previous closing price of $6.31. Analysts anticipate DiaMedica Therapeutics Inc stock to reach 10 by 2025, with the lowest price target being 7. In spite of this, 3 analysts ranked DiaMedica Therapeutics Inc stock as Buy at the end of 2025. On April 09, 2021, Oppenheimer assigned a price target of “an Outperform” to the stock and initiated coverage with a $27.
